Modalis Therapeutics Reports January

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 2, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Modalis Therapeutics Reports January Exercise of Warrant Issue

Source disclosure: February 02, 2026 Modalis Therapeutics Corporation [4883.T] TOKYO, Feb 02 (Pulse News Wire) – Modalis Therapeutics Corporation (4883.T) reported the exercise status of its 17th warrant issue (with adjustment clause) allocated to EVO Fund for January 2026. A total of 810,000 shares were delivered based on the exercise of 8,100 warrants during the month, representing a 4.2% ratio of the total issuance of 192,000 warrants. As of the end of January, there were 86,500